<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82211">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787448</url>
  </required_header>
  <id_info>
    <org_study_id>B3491007</org_study_id>
    <nct_id>NCT01787448</nct_id>
  </id_info>
  <brief_title>RIPT of Ibuprofen Topical Gel</brief_title>
  <official_title>Repeat-insult Patch Test (Ript) of Ibuprofen 5% Topical Gel in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine the potential of Ibuprofen 5% Topical Gel and its
      vehicle gel to cause sensitization after repeated topical application to healthy skin of
      human subjects under controlled conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Dermal sensitization potential</measure>
    <time_frame>24-72 hours after last patch removal</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Irritancy</measure>
    <time_frame>48-72 hours after each patch application</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>During study through 28 days after last product application</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ibuprofen 5% topical gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical gel vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium lauryl sulfate 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride solution 0.9% (saline)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical gel vehicle</intervention_name>
    <description>0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application</description>
    <arm_group_label>Ibuprofen 5% topical gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical gel vehicle</intervention_name>
    <description>0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application</description>
    <arm_group_label>Topical gel vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium lauryl sulfate 0.1%</intervention_name>
    <description>0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application</description>
    <arm_group_label>Sodium lauryl sulfate 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride solution 0.9% (saline)</intervention_name>
    <description>0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application</description>
    <arm_group_label>Sodium chloride solution 0.9% (saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male or female subjects 18 years of age or older, female subjects of childbearing
        potential and males are using an acceptable form of birth control, subjects are free of
        any systemic or dermatologic disorder

        Exclusion Criteria:

        Have any visible skin disease at the application site, not willing to stop use of systemic
        or topical analgesics, corticosteroids, or antihistamines, not willing to stop use of
        sunscreens, creams, or similar products on the back during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Carlstadt</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3491007&amp;StudyName=RIPT%20of%20ibuprofen%20topical%20gel</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 27, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>repeat insult patch test</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
